Guidance on the use of riluzole (Rilutek) for the treatment of motor neurone disease

  • Technology appraisal guidance
  • TA20
  • Published: 
Download guidance (PDF)

10 Sources of evidence

The following documentation and opinion was made available to the committee:

  • Assessment reports:

    • Stewart A, Sandercock J, Bryan S, et al. (2000) The clinical effectiveness and cost effectiveness of Riluzole in the Treatment of Motor Neurone Disease. West Midlands Development & Evaluation Service, University of Birmingham

    • Update assessment report prepared by the West Midlands Development and Evaluation Service

  • Manufacturer/sponsor submissions:

    • Aventis Pharma

  • Professional/specialist group, patient/carer group and trade association submissions:

    • Association of British Neurologists and Royal College of Physicians

    • Association for Palliative Medicine of Great Britain and Ireland

    • Chartered Society of Physiotherapy

    • Motor Neurone Disease Association

    • Royal College of General Practitioners

    • Royal College of Nursing

    • Royal College of Speech and Language Therapists

  • External expert and patient advocate submissions:

    • Professor Pamela Shaw, Section of Neurology, Royal Hallamshire Hospital, Sheffield

    • Ms Julia Johnson, Speech and Language Therapist, King's College Hospital

    • Mr George Levvy, Chief Executive, MND Association

    • Mr Chris Davies, Member of MND Association.

ISBN: 978-1-4731-5618-0